Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
Article
PubMed
Google Scholar
Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, et al. The current state of preclinical prostate cancer animal models. Prostate. 2008;68(6):629–39.
Article
PubMed
PubMed Central
Google Scholar
Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73(9):2718–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Parisotto M, Metzger D. Genetically engineered mouse models of prostate cancer. Mol Oncol. 2013;7(2):190–205.
Article
CAS
PubMed
Google Scholar
Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate. 2002;53(1):24–33.
Article
CAS
PubMed
Google Scholar
Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51.
Article
CAS
PubMed
Google Scholar
Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531–3.
Article
CAS
PubMed
Google Scholar
Collins FS, Tabak LA. NIH plans to enhance reproducibility. Nature. 2014;505:612–3.
Article
PubMed
PubMed Central
Google Scholar
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One. 2009;4(11):e7824.
Article
PubMed
PubMed Central
Google Scholar
Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 2009;69(18):7466–72.
Article
CAS
PubMed
Google Scholar
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hollingshead MG. Antitumor efficacy testing in rodents. J Natl Cancer Inst. 2008;100(21):1500–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Investig. 2002;82(11):1563–71.
Article
PubMed
Google Scholar
Jiang ZK, Sato M, Wei LH, Kao C, Wu L. Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res. 2011;71(19):6250–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res. 2007;67(15):7525–33.
Article
CAS
PubMed
Google Scholar
Seethammagari MR, Xie X, Greenberg NM, Spencer DM. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res. 2006;66(12):6199–209.
Article
CAS
PubMed
Google Scholar
Baker M. Whole-animal imaging: The whole picture. Nature. 2010;463(7283):977–80.
Article
CAS
PubMed
Google Scholar
Nastiuk KL, Liu H, Hamamura M, Muftuler LT, Nalcioglu O, Krolewski JJ. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol. 2007;7:12.
Article
PubMed
PubMed Central
Google Scholar
Davis JS, Nastiuk KL, Krolewski JJ. TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable. Mol Endocrinol. 2011;25(4):611–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Greco A, Mancini M, Gargiulo S, Gramanzini M, Claudio PP, Brunetti A, et al. Ultrasound biomicroscopy in small animal research: applications in molecular and preclinical imaging. J Biomed Biotechnol. 2012;2012:519238.
Article
CAS
PubMed
Google Scholar
Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology. 2003;144(6):2269–78.
Article
CAS
PubMed
Google Scholar
Valkenburg KC, Williams BO. Mouse models of prostate cancer. Prostate Cancer. 2011;2011:895238.
Article
PubMed
PubMed Central
Google Scholar
Lai KP, Huang CK, Fang LY, Izumi K, Lo CW, Wood R, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol. 2013;27(10):1617–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sramkoski RM, Pretlow 2nd TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999;35(7):403–9.
Article
CAS
PubMed
Google Scholar
Alcazar JL, Cabrera C, Galvan R, Guerriero S. Three-dimensional power Doppler vascular network assessment of adnexal masses: intraobserver and interobserver agreement analysis. J Ultrasound Med. 2008;27(7):997–1001.
PubMed
Google Scholar
Bland JM, Altman DG. Measurement error and correlation coefficients. BMJ. 1996;313(7048):41–2.
Article
CAS
PubMed
PubMed Central
Google Scholar
Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer. 2004;11(2):225–54.
Article
CAS
PubMed
Google Scholar
Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.
Article
CAS
PubMed
Google Scholar
Kasper S, Smith Jr JA. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol. 2004;172:12–9.
Article
CAS
PubMed
Google Scholar
Sugimura Y, Cunha GR, Donjacour AA. Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod. 1986;34(5):973–83.
Article
CAS
PubMed
Google Scholar
Nastiuk KL, Kim JW, Mann M, Krolewski JJ. Androgen regulation of FLICE-like inhibitory protein gene expression in the rat prostate. J Cell Physiol. 2003;196(2):386–93.
Article
CAS
PubMed
Google Scholar
Brodoefel H, Burgstahler C, Sabir A, Yam CS, Khosa F, Claussen CD, et al. Coronary plaque quantification by voxel analysis: dual-source MDCT angiography versus intravascular sonography. AJR Am J Roentgenol. 2009;192(3):W84–9.
Article
PubMed
PubMed Central
Google Scholar
Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, Deal BC, et al. Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med. 2010;29(6):891–901.
PubMed
PubMed Central
Google Scholar
Wirtzfeld LA, Wu G, Bygrave M, Yamasaki Y, Sakai H, Moussa M, et al. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res. 2005;65(14):6337–45.
Article
CAS
PubMed
Google Scholar
Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545–57.
Article
CAS
PubMed
Google Scholar
Kyprianou N, Isaacs J. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 1988;122:552–62.
Article
CAS
PubMed
Google Scholar
Maini A, Archer C, Wang CY, Haas GP. Comparative pathology of benign prostatic hyperplasia and prostate cancer. In Vivo. 1997;11(4):293–9.
CAS
PubMed
Google Scholar
Suwa T, Nyska A, Haseman JK, Mahler JF, Maronpot RR. Spontaneous lesions in control B6C3F1 mice and recommended sectioning of male accessory sex organs. Toxicol Pathol. 2002;30(2):228–34.
Article
PubMed
Google Scholar
Sugimura Y, Cunha GR, Donjacour AA. Morphogenesis of ductal networks in the mouse prostate. Biol Reprod. 1986;34(5):961–71.
Article
CAS
PubMed
Google Scholar
Kraaij R, van Weerden WM, de Ridder CM, Gussenhoven EJ, Honkoop J, Nasu Y, et al. Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab Anim. 2002;36(2):165–72.
Article
CAS
PubMed
Google Scholar
Huizen IV, Wu G, Moussa M, Chin JL, Fenster A, Lacefield JC, et al. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. Clin Cancer Res. 2005;11(21):7911–9.
Article
PubMed
Google Scholar
Fricke ST, Rodriguez O, Vanmeter J, Dettin LE, Casimiro M, Chien CD, et al. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate Cancer Models. Prostate. 2006;66(7):708–17.
Article
CAS
PubMed
Google Scholar
Puaux AL, Ong LC, Jin Y, Teh I, Hong M, Chow PK, et al. A comparison of imaging techniques to monitor tumor growth and cancer progression in living animals. Int J Mol Imaging. 2011;2011:321538.
Article
PubMed
PubMed Central
Google Scholar
Laschke MW, Korbel C, Rudzitis-Auth J, Gashaw I, Reinhardt M, Hauff P, et al. High-resolution ultrasound imaging: a novel technique for the noninvasive in vivo analysis of endometriotic lesion and cyst formation in small animal models. Am J Pathol. 2010;176(2):585–93.
Article
PubMed
PubMed Central
Google Scholar
Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, Buckle T, et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques. 2007;43(1 Suppl):7–13. 30.
Article
PubMed
Google Scholar
Elliot TL, Downey DB, Tong S, McLean CA, Fenster A. Accuracy of prostate volume measurements in vitro using three-dimensional ultrasound. Acad Radiol. 1996;3(5):401–6.
Article
CAS
PubMed
Google Scholar
Park SY, Hwang SS. Comparison Of Accuracy Of Prostate Model Volume Measurement Between 2 Dimensional And 3 Dimensional Ultrasonography. Int J Radiol. 2010;14(2):n5.
Google Scholar
Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther. 2006;5(10):2435–43.
Article
CAS
PubMed
Google Scholar